The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
MRI is particularly valuable in pediatric care due to its non-invasive nature
The fresh capital will propel Cordance into its first-in-human clinical trial
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Athena is also exploring the use of this technology for expanded carrier screening
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Subscribe To Our Newsletter & Stay Updated
